Drug intelligence / Profile preview

zamzetoclax

Development stage: Discontinued
Lead developer: Gilead Sciences
Modality: Small Molecules
Administration: Oral

Overview

Zamzetoclax, also known by its former code name GS-9716, is an orally bioavailable small molecule developed by Gilead Sciences. It was investigated for the treatment of advanced solid malignancies. The drug functions as a selective inhibitor of the anti-apoptotic protein myeloid cell leukemia 1 (MCL1), aiming to promote programmed cell death (apoptosis) in cancer cells that overexpress MCL1.

Targets

MCL1 (Myeloid cell leukemia sequence 1)

Beyond the preview

Go deeper on zamzetoclax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on zamzetoclax.

Explore the full profile